Goldman Sachs
CRDF icon

Goldman Sachs’s Cardiff Oncology CRDF Stock Holding History

Goldman Sachs’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,472
Closed -$1.35M – 7105
2015
Q4 		$1.35M Hold
3,472
– – ﹤0.01% 4012
2015
Q3 		$1.42M Buy
+3,472
New +$1.82M ﹤0.01% 4129

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Goldman Sachs's CRDF Position: Q1 2026 in Review

Goldman Sachs reduced its Cardiff Oncology (CRDF) stake by 65% in Q1 2026, selling an estimated $512K and leaving 135,598 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #6041.

Goldman Sachs first reported a position in CRDF in Q2 2015 and has held it in 28 quarters since. The position peaked at $3.14M in Q2 2015. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Goldman Sachs held 135,598 shares of Cardiff Oncology worth $220K as of Q1 2026.
  • Goldman Sachs sold 249,488 Cardiff Oncology shares in Q1 2026, an estimated $512K.
  • Cardiff Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6041 holding.
  • Goldman Sachs first reported a position in Cardiff Oncology in Q2 2015 and has held it in 28 quarters since.
  • Goldman Sachs's Cardiff Oncology position peaked at $3.14M in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.